MegaPro Biomedical Co., Ltd (TPEX:6827)

Market Cap	954.63M
Revenue	n/a
Net Income	n/a
Shares Out	64.72M
EPS	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	63,205
Average Volume	80,513
Open	14.85
Previous Close	14.80
Day's Range	14.50 - 15.15
52-Week Range	8.40 - 22.15
Beta	0.71
RSI	47.33
Earnings Date	n/a

About MegaPro Biomedical

MegaPro Biomedical Co., Ltd, a biotech company, focuses on the development of nano drugs. It also develops MPB-1523, an IOP injection that is in Phase II clinical trial for use in the treatment of hepatocellular carcinoma; and MPB-1514, an iron injection that is in Phase II clinical trial for use in the treatment of iron deficiency anemia, as well as MPB-1734, an anti-cancer drug that is in preclinical trial for the treatment of malignant tumor. The company was founded in 2014 and is based in Zhubei, Taiwan.

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Country: Taiwan
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 6827